ANALYSISApril 13, 2026
Should marijuana be legal for medical use nationwide?
As of early 2026, 40 states plus D.C., Puerto Rico, Guam, and the U.S. Virgin Islands permit medical marijuana, yet cannabis remains a Schedule I controlled substance under federal law. On December 18, 2025, President Trump signed Executive Order 14370 directing the Attorney General to take steps to move marijuana from Schedule I to Schedule III under the Controlled Substances Act. The rescheduling process is ongoing but incomplete, leaving a significant gap between state-level access and federal legal status.
Dozens of states have already said yes, doctors already recommend it, and patients already rely on it — so why is the federal government still treating medical marijuana like a controlled substance with no accepted use? And if Washington finally changes course, who decides what counts as medicine: Congress, the FDA, or the states that got here first?
Not familiar with this story? Get context →
Schedule I classification vs. scientific reality
C
The federal government approved Epidiolex — a cannabis-derived drug — through the FDA in 2018, while simultaneously maintaining that cannabis has 'no accepted medical use' under Schedule I. Those two positions cannot both be true. This is not a policy disagreement; it is an institutional lie that a government committed to the rule of law should find intolerable.
L
The conservative framing here is exactly right, and I'll go further: the HHS completed its own formal scientific review in 2023 and found credible evidence for cannabis in treating pain, chemotherapy-induced nausea, and illness-related anorexia — then recommended rescheduling based on that finding. At that point, Schedule I isn't regulatory caution anymore. It's the federal government contradicting its own health agency.
C
Agreed — and the 2025 meta-study finding weak RCT evidence for many promoted conditions doesn't rescue Schedule I, because that weak evidence was produced under research conditions the scheduling regime itself designed. You cannot suppress research for fifty years and then cite thin findings as justification for continued suppression.
L
Exactly: the meta-study is an indictment of the conditions under which the trials were conducted, not a verdict on cannabis itself. Fund the research, reschedule, resolve the conflict — that sequence is what the science actually demands.
Federal override of 40 state legislatures
C
Forty states have exercised democratic self-determination to create medical cannabis programs — that is Madison's laboratories of democracy functioning as designed. When the federal government responds by trapping those state-legal businesses in a legal gray zone, denying them basic banking, and punishing them through the tax code, the conservative critique should be blistering: this is big government overriding state law, not through democratic deliberation, but through a 1970 scheduling decision that was never meant to be permanent.
L
The federalism point lands, and the democratic math is hard to argue with: 88% of Americans support medical access, 40 states have acted on that consensus, and the federal government's response has been to design a system that punishes compliance rather than accommodate a sustained, three-decade democratic verdict. California legalized medical marijuana in 1996 — Washington is thirty years behind.
C
The thirty-year lag matters precisely because it exposes what Schedule I maintenance actually is at this point: not a considered federal judgment, but bureaucratic inertia insulated from democratic accountability. A conservatism that opposes the administrative state on every other front should oppose it here too.
L
And the voters in those 40 states aren't waiting for federal permission — they've already decided. The only question is whether Washington will keep sabotaging programs its own citizens built.
280E tax code as federal punishment
C
IRS code 280E forces state-licensed cannabis businesses to pay taxes on gross revenue without standard deductions — no write-offs for rent, payroll, or utilities — because Schedule I status triggers the provision. The effective federal tax rate can exceed 70%. This is not drug enforcement; it is the federal government using the tax code to punish small businesses for complying with state law.
L
And it compounds: because those same businesses can't access FDIC-insured banking, they operate cash-only, which makes them robbery targets and makes state tax compliance harder, not easier. The federal government has built a system where following your state's rules makes you more vulnerable and more burdened simultaneously — that's not regulatory caution, that's deliberate sabotage.
C
A conservative who opposes punitive taxation and federal overreach into commerce has no principled basis for defending 280E — it is exactly the kind of regulatory weaponization of the tax code that the right typically fights against, applied here to businesses operating with explicit state authorization.
L
Rescheduling to Schedule III ends 280E liability immediately — no new legislation required. It is the single fastest available relief for the small businesses conservatives say they want to protect.
VA doctors silenced on cannabis
C
Veterans who use cannabis legally under state law cannot receive a recommendation — or even a conversation — from their own VA physician about it. The federal prohibition has made a specific clinical exchange illegal. Whatever one thinks about the medical evidence, a policy that gags doctors from discussing a legal state treatment with patients who have already been failed once is not medical caution — it is the government practicing medicine.
L
This is the sharpest concrete cost of Schedule I status, and it has a specific shape: a veteran in chronic pain, a doctor who knows about their state's program, and a legal prohibition on the most basic clinical conversation. That silence isn't protecting anyone. It's the federal government deciding it knows more than the veteran's own physician about what information that patient should receive.
C
The liberal framing — 'the government practicing medicine' — actually understates it. The VA prohibition doesn't just restrict recommendations; it restricts discussion, which means it operates upstream of clinical judgment entirely. That's not a regulatory guardrail, it's a gag rule.
L
And the irony is that rescheduling alone would not lift this restriction — it would take specific legislative action — which means Congress needs to act even after Schedule III, or the gag on VA physicians continues regardless of what the DEA does.
Rescheduling as minimum coherence threshold
C
Schedule III rescheduling is not recreational legalization and should not be confused for it. It is the minimum act of institutional honesty available: acknowledging that a substance is not medically worthless when the government's own health agency says it has medical value. Trump's Executive Order 14370 directing rescheduling is the correct instinct, but it needs to be understood as the beginning of ordered reform — complete rescheduling, unlock the research pipeline, then build the FDA framework — not the end of it.
L
The 'ordered reform' framing is reasonable, but the sequencing conservative critics propose has a fifty-year track record of producing no reform at all. 'Wait for the FDA framework' has been the answer since 1970 while millions of patients, forty state legislatures, and the government's own health agency concluded the wait was indefinite by design.
C
That critique of sequencing is fair — but it argues for moving faster through the sequence, not abandoning it. The FDA approval pathway matters: Schedule III without a functional dispensary framework risks normalizing products that have never cleared basic evidentiary standards, which is a legitimate concern that 'just reschedule' doesn't resolve.
L
Agreed that the pathway matters — but the research pipeline that would build that pathway has been locked shut by Schedule I for half a century. You cannot demand FDA-standard evidence while maintaining the classification that makes FDA-standard research nearly impossible to conduct.
Racial disparity in cannabis enforcement
C
The enforcement disparity — Black Americans arrested for possession at 3.73 times the rate of white Americans despite comparable use rates — is real data and a genuine injustice. But rescheduling to Schedule III addresses federal research and tax law, not street-level enforcement patterns, which are driven by local policing discretion. Conflating the two risks overpromising what rescheduling actually delivers for communities most harmed by the drug war.
L
The conservative point on limits is technically accurate, but federal prohibition is the legal architecture that makes that disparity durable — it sets the floor for how seriously states and localities treat cannabis, it funds enforcement through federal grants, and it signals that possession is an appropriate subject for aggressive policing. Rescheduling alone doesn't end the disparity, but maintaining Schedule I actively sustains the conditions that produce it.
C
If the argument is that federal scheduling sets a cultural and legal signal that flows downstream into local enforcement, that's a real mechanism worth taking seriously — but it also means full descheduling, not just Schedule III, would be required to move the signal meaningfully. Schedule III still criminalizes non-approved use.
L
That's a genuine tension, and it's why rescheduling is the floor of this debate, not the ceiling — but the choice right now is between that floor and the current architecture, and the current architecture is the one producing 3.73-to-one arrest ratios today.
Conservative's hardest question
The 2025 meta-study covering 15 years of randomized clinical trial data is genuinely difficult to dismiss: if medical evidence for cannabis is weaker than advocates claim, rescheduling and expanded access may normalize a public health intervention whose benefits are not yet scientifically validated. A rigorous conservative must acknowledge this tension rather than paper over it.
Liberal's hardest question
The 2025 meta-study of 15 years of randomized clinical trial data finding insufficient evidence for cannabis across most promoted conditions — including acute pain — is genuinely difficult to dismiss and suggests that state medical programs may have expanded faster than the rigorous evidence base. This does not vindicate Schedule I status, but it does complicate the claim that federal rescheduling is simply a matter of science catching up with obvious medical reality.
Both sides agree: Both sides agree that the 2025 meta-study's findings are genuine and cannot be dismissed, and that the Schedule I designation has actively suppressed the very research that would resolve the evidentiary dispute.
The real conflict: They disagree on a factual-interpretive question: whether the 2025 meta-study's weak findings reflect cannabis's actual limited medical efficacy or are an artifact of the research conditions Schedule I created — a distinction that cannot currently be resolved because Schedule I has prevented the studies needed to settle it.
What nobody has answered: If the evidentiary weakness the 2025 meta-study found is partly a product of Schedule I suppressing rigorous research, and rescheduling is the remedy — but rescheduling may also entrench expanded access before better evidence exists — how should policy sequence those two risks when the costs of waiting fall entirely on current patients and the costs of moving fall on future ones?
Sources
- Web search results provided: comprehensive summary of federal and state medical marijuana legal landscape as of April 2026
- Executive Order 14370, 'Increasing Medical Marijuana and Cannabidiol Research,' December 18, 2025
- HHS recommendation to DEA to reschedule marijuana, 2023
- DEA proposed rescheduling rule, 2024
- Pew Research Center poll on marijuana legalization, 2024
- Quinnipiac University poll on medical marijuana, 2019
- Gallup poll on marijuana legalization, October 2025
- 2025 meta-study of 15 years of cannabis randomized clinical trial research (cited in search results)
- ACLU data on racial disparities in cannabis arrests (cited in search results)
- STATES 2.0 Act, introduced by Representatives David Joyce (R-OH), Max Miller (R-OH), and Dina Titus (D-NV)